Chan Soon-Shiong Institute for Medicine

What Chan Soon-Shiong Institute for Medicine does

Chan Soon-Shiong Institute for Medicine (CSSIFM) is a private, nonprofit medical institute and clinical trial site headquartered in El Segundo, California, founded in 2017 by Dr. Patrick Soon-Shiong. It operates as a hybrid oncology care center and translational research site, delivering standard-of-care cancer treatment alongside Phase 1 through Phase 3 immunotherapy clinical trials. The institute primarily serves adult oncology patients across multiple tumor types as well as Long COVID patients enrolled in investigational protocols, functioning as the clinical-translational arm of the broader Soon-Shiong biomedical ecosystem that includes ImmunityBio, NantHealth, and NantWorks.

The institute's clinical portfolio is anchored by proprietary immunotherapy platforms developed within the Soon-Shiong ecosystem, including NAI (also known as N-803 or Anktiva, an IL-15 superagonist), PD-L1 t-haNK (PD-L1-targeted natural killer cells), M-CENK (cytokine-enhanced NK cells), and the small molecule agent AT-1965. Six protocols are currently active — glioblastoma, non-small cell lung cancer (Phase 3 N-803 + tislelizumab + docetaxel), Long COVID, lymphopenia, ovarian cancer, and a broader solid tumor basket — with publicly announced expansion into HPV, pancreatic, colon, hepatocellular carcinoma, prostate, head and neck, and non-Hodgkin lymphoma indications.

CSSIFM generates revenue through two channels: standard-of-care oncology services reimbursed by commercial insurers (Aetna PPO, Anthem PPO, Blue Shield CA PPO, CIGNA PPO) and government payers (Medicare, Medicare Advantage PPO, Tricare), and clinical trial services funded primarily by ImmunityBio as sponsor. As a nonprofit, it does not raise traditional venture capital and is dependent on the financial and pipeline health of its ecosystem sponsor for trial-driven revenue.

Name

Chan Soon-Shiong Institute for Medicine

Legal name

Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, Mariposa

Website

https://cssifm.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Chan Soon-Shiong Institute for Medicine is a nonprofit cancer care and clinical trial site in El Segundo, California, founded in 2017 by Dr. Patrick Soon-Shiong. It delivers standard-of-care oncology and Phase 1-3 immunotherapy trials using ImmunityBio's proprietary NK-cell and IL-15 superagonist platforms.

Ownership category

akta.pro rank

Product category

Oncology Clinical Research and Immunotherapy Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Medical Laboratories (621511)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

akta.pro secondary industry

Medical Oncology (HLAKAFAB)

Keywords

• Cancer immunotherapy
• Clinical trials
• Cell therapy
• NK cell therapy
• Oncology services

Headquarters

HQ city

El Segundo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Clinical Trial Services: CSSIFM conducts clinical trials testing new treatments for cancer and other conditions. Treatment costs are covered by the trials, but standard-of-care therapy costs may be the responsibility of the patient and/or insurance company.
2. Patient Treatment Services: Provides standard of care cancer treatment, registered dietitian services, vaccine services, blood transfusion services, apheresis program, therapeutic phlebotomy, and nutritional therapy. Accepts insurance plans including Aetna PPO, Anthem PPO, Blue Shield of CA PPO, CIGNA PPO, Medicare, Medicare Advantage PPO, and Tricare.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

CSSIFM runs clinical trials and delivers integrated cancer care built around proprietary immunotherapy platforms (N-803/Anktiva, PD-L1 t-haNK, M-CENK, AT-1965) across glioblastoma, lung cancer, ovarian cancer, solid tumors, lymphopenia, and long COVID. It complements investigational treatment with in-house supportive services including standard-of-care oncology, apheresis, blood transfusion, therapeutic phlebotomy, vaccine administration, registered dietitian services, and nutritional therapy for enrolled patients and trial participants.

Product overview

The Chan Soon-Shiong Institute for Medicine (CSSIFM) is a state-of-the-art cancer care center offering immunotherapy-based clinical trials and treatment services. The organization's core product portfolio centers on its Immunotherapy Bioshield Platform, which combines two proprietary biotechnology products: Nogapendekin Alfa Inbakicept (NAI/ANKTIVA/N-803), an IL-15 superagonist, and PD-L1 t-haNK, an activated natural killer cell therapy. These are complemented by M-CENK Adoptive Cell Therapy and the investigational AT-1965. CSSIFM conducts multiple Phase 1/2/3 clinical trials across various cancer types (glioblastoma, lung, ovarian, lymphopenia, solid tumors) and Long COVID, utilizing combination regimens including chemotherapy agents (gemcitabine, docetaxel), bevacizumab, tislelizumab, and Tumor Treating Fields (TTFields). Beyond clinical trials, the organization provides supporting healthcare services including registered dietitian/nutritional therapy, vaccine services, blood transfusion services, apheresis program, therapeutic phlebotomy, and standard of care treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trials Program
• Standard of Care Treatment
• Apheresis Program
• Blood Transfusion Services
• Therapeutic Phlebotomy
• Vaccine Services
• Registered Dietitian Services
• Nutritional Therapy
• N-803 (Anktiva) Proprietary IL-15 superagonist (marketed as Anktiva) administered as part of CSSIFM clinical protocols, used to stimulate NK and T-cell activity in cancer and immune-deficiency indications.
• PD-L1 t-haNK Engineered NK-cell therapy targeting PD-L1, administered at CSSIFM as part of combination immunotherapy protocols in oncology trials.
• M-CENK Memory cytokine-enriched NK-cell therapy administered at CSSIFM as part of investigational cancer treatment regimens.
• AT-1965 Investigational therapy offered through CSSIFM's clinical pipeline, associated with the institute's oncology research program.

Quantifiable outcome

• Complete responses achieved in Merkel Cell Carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer with combination immunotherapy
• +1 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• ImmunityBiocoreStrategic or Co-development PartnerCSSIFM conducts clinical trials utilizing ImmunityBio's proprietary immunotherapy platforms including Anktiva (N-803), PD-L1 t-haNK, and M-CENK cell therapy. Dr. Patrick Soon-Shiong founded ImmunityBio and the companies share deep operational integration with common leadership. CSSIFM serves as a clinical site for ImmunityBio's immunotherapy pipeline including cancer and Long COVID trials.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Translational Research in Oncology (TRIO): Global clinical research organization specializing in oncology trials with investigator site networks; comparable in trial execution capabilities for novel immunotherapy regimens.
• City of Hope: Major NCI-designated cancer center conducting extensive immuno-oncology clinical trials, including cellular therapy and NK cell platforms, with similar investigator-initiated and industry-sponsored trial mix to CSSIFM.
• Carolina BioOncology Institute: Community-based early-phase oncology clinical trial site specializing in immunotherapy and cellular therapy trials, similar in scale and patient population to CSSIFM.
• START (South Texas Accelerated Research Therapeutics): Network of Phase 1 oncology clinical trial centers conducting immunotherapy and cellular therapy trials; comparable to CSSIFM in its early-phase trial focus and investigator-driven enrollment model.
• Sarah Cannon Research Institute: One of the largest community-based clinical trial site networks in oncology, running early-phase immunotherapy trials at scale; directly comparable as a high-enrollment immunotherapy trial site.
• NEXT Oncology: Specialized early-phase oncology clinical trial site network focused on first-in-human immunotherapy studies; similar business model of enrolling patients into novel cell therapy and immuno-oncology trials.

Others

• ImmunityBio: Closest strategic partner and developer of all proprietary therapies (Anktiva/N-803, PD-L1 t-haNK, M-CENK) administered at CSSIFM; not a peer in the competitive sense but the upstream drug developer whose pipeline directly drives CSSIFM's trial portfolio.

Broad incumbents

• Moffitt Cancer Center: NCI-designated cancer center with significant immuno-oncology and cellular therapy trial activity; similar patient population focus and trial mix to CSSIFM.
• Memorial Sloan Kettering Cancer Center: Leading academic cancer center with extensive cellular immunotherapy and NK cell trial programs; broader scope but directly comparable trial portfolio in immuno-oncology.
• MD Anderson Cancer Center: Premier NCI-designated cancer center running hundreds of immunotherapy and cellular therapy trials; broader portfolio than CSSIFM but a benchmark for clinical trial reputation in oncology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/cssifm

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chan Soon-Shiong Institute for Medicine